POINT Biopharma’s $125 Million Common Stock Offering

Latham & Watkins represented the underwriters in the offering.POINT Biopharma Global Inc. (NASDAQ: PNT), a company accelerating the discovery, development and global access to life-changing radiopharmaceuticals,…

This content is for Standard 1 Year members only.
Login Join Now
Laura Testa

Author: Laura Testa

This content is for Standard 1 Year members only.
Login Join Now